Does Rexulti Interact with Amiodarone?
Yes, there is a clinically significant drug interaction between Rexulti (brexpiprazole) and amiodarone that requires dose adjustment of Rexulti.
Mechanism of Interaction
Amiodarone is a potent inhibitor of CYP3A4 (and also CYP2D6 to a lesser extent), which are the primary enzymes responsible for metabolizing brexpiprazole 1, 2. When amiodarone inhibits these pathways, brexpiprazole levels increase substantially, raising the risk of adverse effects.
Required Dose Adjustment
You must reduce the Rexulti dose when co-administered with amiodarone 3. The FDA label for Rexulti provides explicit guidance:
- If the patient is on a strong CYP3A4 inhibitor alone (which amiodarone is): Reduce Rexulti to half the usual dose
- If the patient is on both a CYP3A4 inhibitor AND a CYP2D6 inhibitor: Reduce Rexulti to one-quarter of the usual dose
Since amiodarone inhibits both CYP3A4 and CYP2D6 1, 2, the more conservative approach would be to reduce brexpiprazole to one-quarter of the usual dose, though the primary concern is the CYP3A4 inhibition.
Clinical Implications
Cardiovascular Monitoring Considerations
While the pharmacokinetic interaction is clear, there are additional cardiovascular concerns when combining these medications:
QT prolongation risk: Both amiodarone and brexpiprazole can affect cardiac conduction. Amiodarone causes QT prolongation in virtually all patients 1, though torsades de pointes is rare. Antipsychotics like brexpiprazole also carry QT prolongation risk.
Monitor for: Bradycardia, heart block, and arrhythmias, particularly during the first weeks of combined therapy 1
Practical Management Algorithm
Before starting combination:
- Obtain baseline ECG
- Check electrolytes (potassium, magnesium)
- Review complete medication list for other QT-prolonging drugs
Dose adjustment:
- Reduce Rexulti dose by 50% (or to 25% if other CYP2D6 inhibitors present)
- Do NOT adjust amiodarone dose based on this interaction
Monitoring during therapy:
- Repeat ECG within 1-2 weeks of starting combination
- Monitor for extrapyramidal symptoms (akathisia is most common with brexpiprazole) 4
- Watch for signs of excessive antipsychotic effect (sedation, orthostasis)
Important Caveats
The interaction is bidirectional in timing: Because amiodarone has an extremely long half-life (weeks to months), this interaction persists for weeks to months even after discontinuing amiodarone 1, 2
Grapefruit juice should be avoided with both medications, as it further inhibits CYP3A4 and can increase levels of both drugs 1, 2
In vitro studies confirm brexpiprazole is unlikely to significantly affect amiodarone levels, so the concern is primarily amiodarone increasing brexpiprazole exposure 5
Bottom line: This combination requires mandatory dose reduction of Rexulti and cardiovascular monitoring, but can be used safely with appropriate precautions.